EU CBD Breakthrough: EFSA's First Positive Safety Opinion — But There's a Catch

On September 18, 2026, EFSA published a positive safety opinion on a synthetic CBD product intended for use in food supplements. This was the first favourable assessment of a CBD novel-food application. For years, European authorities have studied CBD to better understand its safety. Many questions have remained open. The new opinion shows that a CBD product can receive a positive scientific assessment when enough safety data is available. However, the decision only covers the product that EFSA reviewed. It does not apply to every CBD oil, flower, extract, or other CBD product sold in Europe. This is an important difference for businesses that operate across the European market.

First, it is important to understand that EFSA did not issue a market approval. Instead, it published a positive scientific safety opinion. The product reviewed was synthetic CBD made through a controlled chemical process. It had the following features: - CBD purity of at least 98%. - CBD mixed with MCT oil. - Intended use in food supplements. - Maximum daily intake of 2 mg. - Intended for adults aged 25 and older. The favourable safety conclusion did not cover pregnant or breastfeeding women. EFSA also could not establish safety for people taking medication. These limits matter. They show that the decision was based on a specific product, a low daily intake, and a defined group of adults. The findings cannot be applied to all CBD products or doses.

No. EFSA evaluates scientific evidence. It does not grant general permission to sell CBD products. The European Commission is responsible for the EU novel-food authorisation process. A positive EFSA opinion is an important step, but it is not the final legal decision. Businesses must still follow the rules that apply to their products and target markets.

The European CBD market has grown over the years. Yet rules and safety questions have created challenges for companies. In 2022, EFSA reported that important safety data was missing. Scientists raised questions about the possible effects of CBD on the liver, nervous system, hormones, and reproductive health. In February 2026, EFSA took another step. It set a provisional safe intake level of about 2 mg of CBD per day for a 70 kg adult. This level only applied to certain highly pure CBD food supplements. It was not a general recommendation for every CBD product. Then came the September opinion. For the first time, EFSA found that a specific synthetic CBD product was safe under its proposed conditions. This is a meaningful change. It shows that a positive scientific result is possible. It also shows how important strong safety data can be. For the industry, this may help clarify what evidence companies need to submit in future applications.

CBD can come from two main sources. Natural CBD is extracted from the hemp plant, Cannabis sativa L. Synthetic CBD is made through chemical synthesis. Both can contain the same cannabidiol molecule. However, the way CBD is made can affect the final product. Different production methods may leave different impurities or unwanted substances. This is one reason why regulators examine each product on its own.

Just three days after the positive synthetic CBD opinion, EFSA published another assessment. This one concerned CBD extracted from hemp. The proposed product contained at least 98% CBD and was intended as a food supplement at up to 60 mg per day. EFSA could not establish its safety. The reason was not simply that the CBD came from a plant. The assessment found gaps in the available data. The applicant did not provide the extra information requested by EFSA. This is an important point. The two opinions do not prove that synthetic CBD is always safer than natural CBD. They show that safety assessments depend on the product, the proposed dose, and the quality of the evidence.

The September decision matters beyond the food supplement market. It offers useful lessons for CBD producers, manufacturers, brands, and distributors. 1. Product Quality Matters CBD buyers need clear information about what they purchase. Reliable laboratory tests can help confirm cannabinoid levels and detect unwanted substances. Batch records and product specifications also support better quality control. However, laboratory results alone do not prove that a product has legal approval. 2. Clear Documentation Is Essential Businesses should know where their products come from and how they are made. Useful documents may include certificates of analysis, product specifications, and traceability records. These help buyers make informed decisions. They also make it easier to review the rules that apply to a product. 3. Different Products Have Different Rules CBD is sold in many forms. These include flowers, hash, extracts, cosmetics, vapes, and food supplements. Not all these products follow the same legal framework. The September EFSA opinion concerns CBD intended for food supplements. It does not approve CBD flowers, hash, or vaping products. Businesses must check the rules for each product type. 4. European Markets Are Not All the Same CBD companies often sell across several countries. Yet national laws and enforcement practices can differ. A product that can be sold in one country may face different requirements in another. For wholesale businesses, understanding the destination market remains essential.

The September decision is a positive step, but many questions remain. Europe is still working through a complex process of scientific reviews and legal decisions. Some CBD applications may receive favourable opinions. Others may need more data. A positive assessment also does not guarantee market authorisation. For businesses, this means it is important to follow official updates rather than rely on headlines. The European Commission, EFSA, and national authorities remain key sources of information. As more scientific evidence becomes available, some parts of the regulatory process may become clearer. Still, it is too early to say how quickly the wider CBD market will change.

For wholesale buyers, the main lesson is simple: stay informed and check the facts. Before working with a supplier, businesses should understand the product, its origin, and its intended use. They should also review available quality documents and check the laws of the country where the product will be sold. A positive EFSA opinion can be an important industry development. But it should never be used as proof that unrelated CBD products are approved. Reliable information helps companies avoid costly mistakes and build stronger business relationships.

The next steps will depend on future scientific reviews and decisions by the European Commission. Several areas deserve attention. More CBD applications may undergo safety assessments. New studies may provide better information about long-term use and possible health risks. European authorities may also update their guidance as new evidence becomes available. For now, the September 2026 decision marks progress, not the end of the regulatory process. It is an important milestone in a market that continues to develop.

September 2026 brought important news for the European CBD sector. EFSA's first positive safety opinion on a specific synthetic CBD product shows that scientific progress is possible. But the decision has clear limits. It does not approve all CBD products or remove the need for legal checks. For manufacturers, suppliers, and wholesale buyers, the message is clear: quality, reliable data, and regulatory knowledge matter more than ever. At Hemporium, we follow developments across the European CBD industry to help businesses stay informed. From scientific research to changes in market rules, our goal is to share clear, useful information for CBD professionals. Stay informed. Stay prepared. Explore the future of CBD with Hemporium. Disclaimer: This article is for general information only. It is not legal or medical advice. CBD rules vary by product and country. Always check current requirements before placing products on the market. Sources and Further Reading EFSA — Safety of Synthetic Cannabidiol as a Novel Food (September 2026) EFSA — Safety of CBD Isolated from Cannabis sativa L. (September 2026) EFSA — Provisional Safe Level for CBD (February 2026) European Commission — Novel Food Authorisations